Georges Gebrael, Research Fellow at Huntsman Cancer Institute and University of Utah, shared an article he and colleagues authored on X:
“Just in Prostate Cancer and Prostatic Diseases Journal.
TP53, RB1, PTEN worse PFS and OS in patients with mHSPC treated with ADTi.
After ext validation in larger and prosp datasets can help in prognostication and guide MDM.”
Authors: Georges Gebrael et al.
